HIGH LEVEL OF COBLL1, A NOVEL ROR1 BINDING PARTNER, IDENTIFIES CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH MUTATED IGHV

被引：0

作者：

Plesingerova, H. ^{[1
,2
]}

Janovska, P. ^{[3
]}

Shaik, A. ^{[3
]}

Poppova, L. ^{[1
,2
]}

Libra, A. ^{[4
]}

Plevova, K. ^{[1
,2
,3
]}

Machac, J. ^{[5
]}

Slapak, I. ^{[5
]}

Pavlova, S. ^{[1
,2
,3
]}

Pospisilova, S. ^{[1
,2
]}

Bryja, V. ^{[3
,6
]}

机构：

[1] Cent European Inst Technol, Brno, Czech Republic

[2] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic

[3] Masaryk Univ, Fac Sci, Inst Expt Biol, CS-61137 Brno, Czech Republic

[4] Generi Biotech Sro, Hradec Kralove, Czech Republic

[5] Masaryk Univ, Fac Med, Univ Hosp Brno, Clin Pediat Ear Nose & Throat Dis, Brno, Czech Republic

[6] Acad Sci Czech Republic, Inst Biophys, Dept Cytokinet, CS-61265 Brno, Czech Republic

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P195

引用

页码：39 / 39

页数：1

共 50 条

[31] Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells
Mellstedt, Hakan
Khan, Salam
Vagberg, Jan
Bystrom, Styrbjorn
Schultz, Johan
Farsangi, Mohammad Hojat
Mansouri, Ladan
Manesh, Amir Hossein Danesh
Osterborg, Anders
Moshfegh, Ali
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] Ror1 Targeting Monoclonal Antibodies Induced Apoptosis of Chronic Lymphocytic Leukemia Cells- A Potential Novel Therapeutic Approach
Rabbani, Hodjattallah
Daneshmanesh, Amir Hossein
Khan, Abdul Salam
Hojjat-Farsangi, Mohammad
Jeddi-Tehrani, Mahmood
Akhondi, Mohammad Mehdi
Osterborg, Anders
Shokri, Fazel
Mellstedt, Haakan
BLOOD, 2010, 116 (21) : 404 - 404
[33] Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
Hasan, M. K.
Yu, J.
Chen, L.
Cui, Bing
Widhopf, G. F., II
Rassenti, L.
Shen, Z.
Briggs, S. P.
Kipps, T. J.
LEUKEMIA, 2017, 31 (12) : 2615 - 2622
[34] EPIGENETIC REGULATION OF ROR1 IN CHRONIC LYMPHOCYTIC LEUKEMIA DEFINES PREFERABLE TARGET FOR COMBINED EPIGENETIC AND IMMUNE THERAPY
Skorka, K.
Karp, M.
Zakrzewska, E.
Zaleska, J.
Zajac, M.
Karczmarczyk, A.
Purkot, J.
Tomczak, W.
Wlasiuk, P.
Matosiuk, D.
Giannopoulos, K.
HAEMATOLOGICA, 2016, 101 : 224 - 224
[35] Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Hu, Eileen
Do, Priscilla
Mani, Rajeswaran
Frissora, Frank
Peng, Haiyong
Waldmeier, Lorenz
Beerli, Roger
Rader, Christoph
Grawunder, Ulf
Byrd, John C.
Muthusamy, Natarajan
BLOOD, 2017, 130
[36] Novel humanised ROR1 Bispecific T-cell Engager for the treatment of chronic lymphocytic leukaemia
Gohil, Satyen
Nathwani, Amit
Harrasser, Micaela
Paredes, Solange
Della Peruta, Marco
LEUKEMIA & LYMPHOMA, 2017, 58 : 230 - 231
[37] Receptor tyrosine kinase-like orphan receptor 1 (ROR1) - a cell signature gene for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL)
Uhrmacher, S.
Schmidt, C.
Filipovich, A.
Erdfelder, F.
Hallek, M.
Kreuzer, K-A
ONKOLOGIE, 2010, 33 : 44 - 44
[38] Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
M K Hasan
J Yu
L Chen
Bing Cui
G F Widhopf II
L Rassenti
Z Shen
S P Briggs
T J Kipps
Leukemia, 2017, 31 : 2615 - 2622
[39] Expression of ROR1 in chronic lymphocytic leukemia cells enhances cells survival by Wnt5a signaling
Chen, Liguang
Tang, Li
Fukuda, Tetsu
Kipps, Thomas J.
BLOOD, 2007, 110 (11) : 107A - 107A
[40] Minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL) via an 8 color flow cytometry panel comprising the signature gene ROR1
Patz, Michaela
Pentok, Barbara
Cremer, Kathrin
Linnartz, Stefanie
Lilienweiss, Esther
Kleinert, Fanni
Hallek, Michael
Kreuzer, Karl-Anton
LEUKEMIA & LYMPHOMA, 2017, 58 : 93 - 94

← 1 2 3 4 5 →